Numerous antiangiogenesis drugs have been developed for the treatment of patients with malignancies. These agents, which include vascular-endothelial-growth-factor inhibitors, microtubule disrupters and fumagillin analogues, might also represent new therapeutic options for patients with proliferative synovitis, as is discussed in this Review.
- Dahlia Lainer-Carr
- Ernest Brahn
